• Bicara Therapeutics posted an ASCO 2026 poster on long-term phase 1/1b expansion cohort results for ficerafusp alfa with pembrolizumab.
• The presentation focuses on response depth and durability in recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.
• The dataset highlights outcomes from two expansion cohorts studying TGF-β trapping combined with PD-1 blockade in this setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.